Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence

SIMPLE SUMMARY: Despite immune checkpoint inhibitors’ (ICIs) improved overall survival in urothelial carcinoma patients, only a minority of them benefit from immunotherapy. Therefore, there is an unmet clinical need to identify biomarkers which are useful to select the patients who are most likely t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebuzzi, Sara Elena, Banna, Giuseppe Luigi, Murianni, Veronica, Damassi, Alessandra, Giunta, Emilio Francesco, Fraggetta, Filippo, De Giorgi, Ugo, Cathomas, Richard, Rescigno, Pasquale, Brunelli, Matteo, Fornarini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583566/
https://www.ncbi.nlm.nih.gov/pubmed/34771680
http://dx.doi.org/10.3390/cancers13215517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583566/
https://www.ncbi.nlm.nih.gov/pubmed/34771680
http://dx.doi.org/10.3390/cancers13215517

Ejemplares similares